Apogee Therapeutics Secures Up to $1.3 Billion from Blackstone for Eczema Drug Development

Apogee Therapeutics secured up to $1.3 billion from Blackstone Life Sciences on May 27, 2026, comprising up to $800 million in royalty funding and up to $500 million in senior debt for its eczema drug zumilokibart. The deal marks the largest royalty financing for a pre-Phase 3 program to date. Mid-stage trial results showed 65.9% of patients on the mid-dose achieved at least 75% improvement in eczema severity after 16 weeks versus 23.4% on placebo.

Blackstone financing deal

• ▪Apogee Therapeutics plans to advance the selected mid-dose of zumilokibart into late-stage studies in the second half of 2026.
• ▪The Apogee Therapeutics financing deal supports late-stage development and potential commercialization of zumilokibart.
• ▪Apogee Therapeutics can access up to another $400 million in royalty funding if zumilokibart gets FDA approval.
• ▪The Apogee Therapeutics-Blackstone financing is the largest royalty financing for a pre-Phase 3 program to date.
• ▪The Apogee Therapeutics financing deal includes up to $800 million through a royalty agreement and access to up to $500 million in senior debt.
• ▪Apogee Therapeutics secured a financing deal with Blackstone Life Sciences worth up to $1.3 billion on May 27, 2026.

Zumilokibart trial results

• ▪Zumilokibart met all main and secondary goals in a mid-stage trial with 346 adults.
• ▪65.9% of patients on the mid-dose of zumilokibart achieved at least a 75% improvement in eczema severity after 16 weeks, compared with 23.4% on placebo.
• ▪Zumilokibart is being developed for moderate-to-severe atopic dermatitis.

Stock market reaction

• ▪The royalty agreement with Blackstone removes the possibility of Apogee Therapeutics being a potential candidate for M&A.
• ▪Apogee Therapeutics shares fell nearly 12% in premarket trading on May 27, 2026.

Analyst assessments

• ▪The zumilokibart high dose underperformed the mid-dose, making the results appear mixed.
• ▪The zumilokibart mid-dose data, combined with less frequent maintenance dosing, support the drug's potential best-in-class profile on efficacy and convenience.

Perspective of Market analysts and investors

• ▪The royalty agreement with Blackstone removes the possibility of Apogee Therapeutics being a potential candidate for M&A.

1 source